文献速递临床试验与 GCP基础与转化研究

I-MICRO试验:伊洛前列素治疗持续微循环障碍的脓毒性休克双盲随机对照试验方案

The I-MICRO trial, Ilomedin for treatment of septic shock with persistent microperfusion defects: a double-blind, randomized controlled trial-study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-07-01

I-MICRO试验为多中心前瞻性随机双盲安慰剂对照研究,计划纳入236例经血流动力学支持后仍存在持续微循环障碍的成人脓毒性休克患者,随机接受48小时静脉输注伊洛前列素或安慰剂,主要结局为随机化至第7天SOFA评分变化。

要点

  • 伊洛前列素是前列环素类似物,优先作用于微循环发挥扩血管和抗血小板聚集效应。
  • 研究对象为脓毒性休克经液体复苏、升压药等支持后仍有皮肤花斑或毛细血管再充盈时间延长的患者。
  • 主要结局为随机化至第7天SOFA评分变化,次要结局包括28天死亡率、无器官支持生存天数等。

核心结论

  • 该试验旨在为伊洛前列素治疗脓毒性休克伴持续微循环障碍的疗效与安全性提供证据。

研究设计与样本

  • 多中心、前瞻性、随机、双盲、安慰剂对照试验,计划招募236例成人脓毒性休克伴持续微循环障碍患者。
  • 受试者在脓毒性休克后最早6小时、最晚24小时开始接受48小时静脉输注伊洛前列素或安慰剂。

主要发现

  • 主要结局为随机化至第7天SOFA评分的变化(delta)。
  • 次要结局包括随机化后前7天平均SOFA评分、随机化后28天死亡率、28天内无机械通气生存天数、28天内无肾脏替代治疗生存天数、28天内无升压药生存天数及随机化后第1天花斑评分。

关键数值与推荐

  • 纳入标准:成人脓毒性休克,经血流动力学支持后仍存在持续微循环障碍,表现为皮肤花斑或毛细血管再充盈时间延长。
  • 主要结局指标:随机化至第7天SOFA评分变化。

临床怎么用

  • 该方案为脓毒性休克伴持续微循环障碍患者使用伊洛前列素提供了随机对照试验框架,结果待试验完成后可指导临床决策。

局限性

  • 本文为试验方案,尚未报告研究结果,无法评估干预的疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Septic shock remains a significant cause of death in critically ill patients. During septic shock, some patients will retain microcirculatory disorders despite optimal hemodynamic support (i.e., fluid resuscitation, vasopressors, inotropes). Alterations in the microcirculation are a key pathophysiological factor of organ dysfunction and death in septic shock patients. Ilomedin is a prostacyclin analog with vasodilatory effect and anti-thrombotic properties (i.e., inhibition of platelet aggregation) preferentially at the microcirculatory level. We hypothesize that early utilization of intravenous Ilomedin in septic shock patients with clinical persistence of microperfusion disorders would improve the recovery of organ dysfunction. METHODS: The I-MICRO trial is a multicenter, prospective, randomized, double-blinded, placebo-controlled study. We plan to recruit 236 adult patients with septic shock and persistent microcirculatory disorders (i.e., skin mottling or increased capillary refill time) despite hemodynamic support. Participants will be randomized to receive a 48-h intravenous infusion of either Ilomedin or placebo starting at the earliest 6 h and later 24 h after septic shock. The primary outcome will be the change (delta) of sequential organ failure assessment (SOFA) score between randomization and day 7. Secondary outcomes will include mean SOFA score during the first 7 days after randomization, mortality at day 28 post-randomization, number of ventilation-free survival days in the 28 days post-randomization, number of renal replacement therapy-free survival days in the 28 days post-randomization, number of vasopressor-free survival days in the 28 days post-randomization, and mottling score at day 1 after randomization. DISCUSSION: The trial aims to provide evidence on the efficacy and safety of Ilomedin in patients with septic shock and persistent microcirculatory disorders. TRIAL REGISTRATION: NCT NCT03788837 . Registered on 28 December 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Legrand M, Oufella HA, De Backer D, et al. The I-MICRO trial, Ilomedin for treatment of septic shock with persistent microperfusion defects: a double-blind, randomized controlled trial-study protocol for a randomized controlled trial. Trials. 2020. PMID: 32611377. doi:10.1186/s13063-020-04549-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。